The biotech licenses a China-developed anti-B7-H3 ADC.
ApexOnco Front Page
Recent articles
Armed with $75m the company takes a risky asset into the clinic.
Readout of the Pivot-006 trial is brought forward by nearly a year.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
After Aktis's $318m flotation Eikon is a bigger proposition.
$650m buys the group rights to RemeGen’s RC148.
ELVN-001 is made to look more like Terns’ TERN-701.
